Compare AHCO & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | ORKA |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | AHCO | ORKA |
|---|---|---|
| Price | $10.51 | $27.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.60 | ★ $48.20 |
| AVG Volume (30 Days) | ★ 1.2M | 719.0K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $3,255,213,000.00 | N/A |
| Revenue This Year | $1.07 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | $18.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.11 | $5.49 |
| 52 Week High | $11.63 | $32.64 |
| Indicator | AHCO | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 44.15 |
| Support Level | $9.53 | $25.23 |
| Resistance Level | $10.38 | $32.64 |
| Average True Range (ATR) | 0.32 | 2.15 |
| MACD | -0.03 | -0.55 |
| Stochastic Oscillator | 82.03 | 34.55 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.